Brief: Panbela Regains Worldwide Rights To Develop And Commercialize Colon Disease Drug
11/04/2023 13:24
April 11 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA REGAINS WORLDWIDE RIGHTS TO DEVELOP AND
COMMERCIALIZE
FLYNPOVITM IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
* PANBELA THERAPEUTICS - REGAINED RIGHTS DUE TO DEAL
TERMINATION
BETWEEN CANCER PREVENTION PHARMACEUTICALS & WITH ONE-TWO
THERAPEUTICS ASSETS LIMITED
Source text for Eikon: ID:nGNX4yw7qs
Further company coverage: PBLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants